One study tied GLP-1 RAs to adverse impacts on the small intestine and blockages in the intestines and stomach
The frequency and intensity vary widely depending on baseline metabolism, starting dose, and individual genetics
Elevated hospitalisation for HF incidence remains a concern, as reported in the SAVOR-TIMI 53 trial.5557 However, in the EXAMINE and the latest CARMELINA trials, HF incidences were neutral.58,59 DPP-4 inhibitors have been reported to inhibit degradation of endogenous peptides other than GLP-1, including stromal-cell-derived factor (SDF) 1, neuropeptide Y and substance P ( Figure 2 ).60 Potentiation of these peptides results in sympathetic activation via cyclic AMP signalling and beta-receptor activation, which may contribute to HF development and cardiac fibrosis
BPC 157/NO-System All of these beneficial effects of BPC 157 therapy can be achieved along with the NO-system (see below), and the controlling/modulating angiogenesis should occur along with similar corresponding controlling/modulating NO-system functioning [11,29,92,93,94,97,98,99]
doi:10.1016/j.aohep.2024.101288 29Eisenberg D, Shikora SA, Aarts E, et al
For readers comparing tirzepatide options and how they are prescribed, How Can I Get Tirzepatide for Weight Loss